Your browser doesn't support javascript.
loading
Indeterminate dendritic cell neoplasm of the skin: A 2-case report and review of the literature.
Horna, Pedro; Shao, Haipeng; Idrees, Afshan; Glass, L Frank; Torres-Cabala, Carlos A.
Affiliation
  • Horna P; Division of Hematopathology, Mayo Clinic, Rochester, Minnesota.
  • Shao H; Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Idrees A; Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Glass LF; Department of Dermatology, George Washington University, Washington, District of Columbia.
  • Torres-Cabala CA; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.
J Cutan Pathol ; 44(11): 958-963, 2017 Nov.
Article in En | MEDLINE | ID: mdl-28880462
Indeterminate dendritic cell neoplasm (IDCN) is an exceedingly rare and mostly cutaneous histiocytosis, frequently associated with other hematopoietic malignancies. We report 2 cases of multilesional cutaneous IDCN. A 55-year-old male with no associated malignancy and complete response to ultraviolet phototherapy; and a 72-year-old male with chronic myelomonocytic leukemia (CMML). Both cases showed histiocytoid cytology, positivity for CD1a and no expression of langerin or BRAFV600E . With our patients, the literature describes 79 cases of IDCNs, including 65 (82%) with only skin involvement, 7 cases (9%) with involvement of skin and a second site, 5 cases (6%) involving lymph nodes only, 1 splenic lesion and 1 systemic disease. Seventeen cases (22%) were associated with other hematopoietic malignancies, most commonly CMML (6 cases), follicular lymphoma (4 cases) and acute myeloid leukemia (3 cases). All IDCNs associated with myeloid malignancies were limited to the skin, while most cases associated with lymphoma were limited to lymph nodes. Reported responses of cutaneous lesions to ultraviolet phototherapy are encouraging, while systemic chemotherapy is appropriate for clinically aggressive cases and treatment of associated malignancies. Recognition of the clinico-morphologic spectrum of IDCNs should prevent misdiagnoses and prompt investigation of possible associated neoplasms.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Langerhans Cells Limits: Aged / Humans / Male / Middle aged Language: En Journal: J Cutan Pathol Year: 2017 Type: Article

Full text: 1 Database: MEDLINE Main subject: Skin Neoplasms / Langerhans Cells Limits: Aged / Humans / Male / Middle aged Language: En Journal: J Cutan Pathol Year: 2017 Type: Article